1. Home
  2. MIRM vs CVCO Comparison

MIRM vs CVCO Comparison

Compare MIRM & CVCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

HOLD

Current Price

$100.65

Market Cap

4.2B

Sector

Health Care

ML Signal

HOLD

CVCO

Cavco Industries Inc. When Issued

HOLD

Current Price

$571.12

Market Cap

4.6B

ML Signal

HOLD

Company Overview

Basic Information
Metric
MIRM
CVCO
Founded
2018
1965
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Homebuilding
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
4.2B
4.6B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
MIRM
CVCO
Price
$100.65
$571.12
Analyst Decision
Strong Buy
Hold
Analyst Count
11
1
Target Price
$102.64
$550.00
AVG Volume (30 Days)
733.0K
249.5K
Earning Date
02-26-2026
01-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
13.44
EPS
N/A
22.97
Revenue
$471,794,000.00
$2,202,736,000.00
Revenue This Year
$55.91
$14.66
Revenue Next Year
$23.97
$7.70
P/E Ratio
N/A
$24.78
Revenue Growth
53.66
14.30
52 Week Low
$36.88
$393.53
52 Week High
$105.74
$713.01

Technical Indicators

Market Signals
Indicator
MIRM
CVCO
Relative Strength Index (RSI) 64.68 48.23
Support Level $97.49 $451.00
Resistance Level $105.74 $713.01
Average True Range (ATR) 3.71 27.22
MACD -0.79 -3.02
Stochastic Oscillator 62.01 54.27

Price Performance

Historical Comparison
MIRM
CVCO

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

About CVCO Cavco Industries Inc. When Issued

Cavco Industries Inc designs and produces factory-built homes under the Cavco Homes, Fleetwood Homes, and Palm Harbor Homes brands. It also produces modular homes, park model homes, and vacation cabins, as well as commercial structures, among others. The company operates principally in two segments: Factory-built housing, which includes wholesale and retail systems-built housing operations, and the Financial services segment, which includes manufactured housing consumer finance and insurance. Cavco receives a majority of its revenue from the Factory-built housing segment.

Share on Social Networks: